Boston Therapeutics Inc. (BTHE)
Stock Price:
$0.0169 USD
0.0069 (69.00%)
Updated Aug 11, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
1.88M |
| Revenue (ttm) |
16,329 |
| Net Income (ttm) |
-3.69M |
| Shares Out |
111.13M |
| EPS (ttm) |
-0.03 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$0.0169 |
| Previous Close |
$0.0100 |
| Change ($) |
0.0069 |
| Change (%) |
69.00% |
| Day's Open |
0.0169 |
| Day's Range |
0.0169 - 0.0169 |
| Day's Volume |
21,000 |
| 52-Week Range |
0.0052 - 0.0332 |
More Stats
| Market Cap |
1.88M |
| Enterprise Value |
5.92M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
111.13M |
| Float |
58.54M |
| EPS (basic) |
-0.03 |
| EPS (diluted) |
-0.03 |
| FCF / Share |
-0.01 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
0.13 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
115.02 |
| PB Ratio |
n/a |
| Revenue |
16,329 |
| Operating Income |
-3.86M |
| Net Income |
-3.69M |
| Free Cash Flow |
-1.20M |
| Net Cash |
-4.04M |
| Net Cash / Share |
-0.04 |
| Gross Margin |
-65.40% |
| Operating Margin |
-23,641.47% |
| Profit Margin |
-22,622.80% |
| FCF Margin |
-7,324.01% |
| ROA |
-298.45% |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
1.80
Current: $0.0169
High
1.80
Target: 1.80
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.02 | 0.03 | 0.03 | 0.10 | 0.10 | 0.20 | 0.32 | 0.04 | - | - |
| Revenue Growth | -48.53% | 8.06% | -70.31% | -0.06% | -50.43% | -38.29% | 665.4% | 927.58% | 860.75% | - |
| Gross Profit | -0.01 | -0.04 | -0.02 | - | -0.14 | 0.02 | 0.05 | -0.01 | - | - |
| Operating Income | -3.86 | -3.28 | -1.27 | -1.26 | -2.10 | -4.67 | -4.58 | -1.46 | -0.81 | -0.24 |
| Net Income | -3.69 | -3.60 | -1.58 | -3.74 | -2.49 | -4.70 | -4.60 | -1.48 | -0.83 | -0.25 |
| Shares Outstanding | 111 | 102 | 51.47 | 43.54 | 39.11 | 38.19 | 25.37 | 16.87 | 15.15 | 10.70 |
| Earnings Per Share | -0.03 | -0.04 | -0.03 | -0.09 | -0.06 | -0.12 | -0.18 | -0.09 | -0.05 | -0.02 |
| Operating Cash Flow | -1.20 | -0.88 | -1.28 | -1.25 | -1.29 | -3.47 | -2.34 | -0.85 | -0.39 | -0.12 |
| Capital Expenditures | - | - | - | - | - | -0.01 | -0.01 | -0.01 | - | - |
| Free Cash Flow | -1.20 | -0.88 | -1.28 | -1.25 | -1.29 | -3.48 | -2.35 | -0.86 | -0.39 | -0.12 |
| Cash & Equivalents | 0.01 | 0.01 | 0.14 | 0.69 | 0.04 | 0.16 | 3.39 | 0.55 | 0.23 | 0.02 |
| Total Debt | 4.05 | 2.83 | 2.50 | 1.42 | 0.39 | 0.30 | 0.30 | 0.30 | - | - |
| Net Cash / Debt | -4.04 | -2.82 | -2.36 | -0.73 | -0.35 | -0.14 | 3.09 | 0.25 | 0.23 | 0.02 |
| Assets | 0.02 | 1.44 | 0.90 | 1.40 | 0.88 | 1.16 | 4.54 | 1.44 | 1.15 | 0.98 |
| Liabilities | 7.70 | 5.59 | 4.79 | 4.52 | 1.41 | 1.09 | 1.19 | 0.74 | 0.73 | 0.45 |
| Book Value | -7.67 | -4.15 | -3.88 | -3.12 | -0.53 | 0.07 | 3.35 | 0.70 | 0.42 | 0.53 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Boston Therapeutics Inc. |
| Country |
United States |
| CEO |
Chi-Heng Cheng |
Stock Information
| Ticker Symbol |
BTHE |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: BTHE |
Description
Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical development company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates are BTI-320, a non-systemic carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. The company also produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement to support healthy post-meal blood glucose. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is headquartered in Lawrence, Massachusetts.